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Elevated Everolimus Levels During Severe Diarrhea in Two
Children After Heart Transplantation
M inimization of side effects of im-munosuppressive therapy after
pediatric heart transplantation is an
important objective of aftercare. Not
only various medications and foods but
also gastrointestinal problems can cause
increased peak levels of immunosup-
pressants. Especially, tacrolimus is well
known for elevated levels during diar-
rhea (1Y3). In the follow-up care of pe-
diatric heart transplanted patients, the
new immunosuppressant everolimus is
increasingly used. However, the influ-
ence of diarrhea on everolimus blood
levels has not been evaluated yet. We
report about two patients with elevated
everolimus levels during severe diarrhea
with at least two watery stools per day.
CASE 1
The 3.5-year-old girl with history of
heart transplantation in June 2010 because
of noncompaction cardiomyopathy was on
immunosuppressive therapy with everolimus
and tacrolimus. The target value of tacro-
limus was 6 ng/mL; the one of everolimus
ranged from 4 to 5 ng/mL. Levels were at
the lower limits (tacrolimus 5.2 ng/mL and
everolimus 2.9 ng/mL) under a daily dosage of
3 mg tacrolimus and 2.5 mg everolimus 1 week
before the occurrence of diarrhea. During one
episode of severe diarrhea, the patient was
admitted to our hospital because of dehy-
dration. The blood trough level of tacrolimus
had increased from 5.2 to 21.6 ng/mL,
whereas everolimus had increased from 2.9 to
13.4 ng/mL. By pausing both immunosup-
pressive medications, the levels decreased
slowly, so that tacrolimus and everolimus
could be continued in a reduced dosage after
2 days (tacrolimus daily dose 2 mg and
everolimus daily dose 1.5 mg). Ten days after
the onset of diarrhea, the levels of both im-
munosuppressants returned to normal values
under a reduced dosage. Furthermore, there
was no need to increase the two immuno-
suppressive medications to the initial dose
before diarrhea within 8 months after diar-
rhea had occurred.
CASE 2
The 13-year-old boy had to undergo
heart transplantation 1998 because of dilated
cardiomyopathy. Thirteen years later, he was
on immunosuppressive therapy with myco-
phenolic acid (MPA) and everolimus. The
target values of MPA were between 0.5 and
4 Hg/mL and stayed within the target range
before, during, and after diarrhea. It was pos-
sible to constantly achieve the target values of
everolimus (between 5 and 8 ng/mL) under a
dosage of 4.75 mg per day. During severe di-
arrhea, the everolimus level rose to 15.6 ng/mL.
Via dose reduction and normalization of the
stool, simply under symptomatic therapy, the
levels went back to normal in about 1 week.
There was no need to change the dosage of
MPA. Interestingly, as in the first case, it was
not possible to return to the initial dose before
diarrhea for more than 1 year.
In both cases, a correlation between
the elevated values and medication or food
was not detectable. There were no changes
of medication, the chronological taking of
everolimus related to food, or initiation of
interacting drugs before the onset of diar-
rhea. In addition, there was no sign of re-
duced hepatic function that could have
explained the elevated levels of everolimus.
It was not possible to identify a specific
cause for the diarrhea in the patients. How-
ever, a viral infection seems most likely.
There are reports on elevated tacrolimus
levels during diarrhea (1Y3). We detected the
same effect with everolimus during diarrhea
in two patients after heart transplantation.
The immunosuppressant everolimus has a
low oral bioavailability of 16% (4). P-glycoprotein
and cytochrome P450 are responsible for the
absorption and metabolism of everolimus (4)
as well as tacrolimus (2). Therefore, the reasons
for elevated tacrolimus levels during diarrhea
could accordingly apply to everolimus. Possible
explanations are decreased activity of cyto-
chrome P450 and P-glycoprotein (2) as well as
a decreased hepatic blood flow with reduced
hepatic metabolism (1). The apices of the en-
terocytes in the small intestine carry cytochrome
P450. Lysis of the enterocytes by viral diarrhea
leads to reduced activity of cytochrome P450
causing decreased intestinal metabolism of im-
munosuppressants with increased blood levels.
In addition, a capacity overload could explain
the concordant change of the immunosuppres-
sant levels in case of a simultaneous taking
of tacrolimus and everolimus.
According to the equivalent hypoth-
eses concerning tacrolimus (2), the lower
dosage for almost 1 year after diarrhea could
be explained by the time required to nor-
malize the activity of cytochrome P450 and
P-glycoprotein.
For the evaluation of the concrete
mechanism of elevated everolimus levels
during diarrhea, further studies are neces-
sary. However, regardless the mechanism
responsible, it is important to know about
the possible increase of everolimus during
diarrhea. A frequent control of everolimus
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